Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


HIV target could fall to Covid

Posted 19 January 2021 AM

Australia's target to boost the proportion of eligible people taking prophylactic HIV medication to 75 per cent by 2022 is in fear of failing, thanks to COVID-19 putting the brakes on people seeking medical care.

PBAC public summary documents show a drop in the uptake of  HIV Pre-Exposure Prophylaxis (PrEP) medications between 2019 and 2020 despite ongoing government and community awareness campaigns - with a sharp drop in prescriptions recorded in April 2020 and subsequent months, coinciding with the onset of restrictions due to the pandemic.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Approvals Action
New registrations for seizures and HIV
Eisai and ViiV add to their core franchises
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas